Tirzepatide

Mounjaro (tirzepatide) hasn’t shown causation with Parkinson’s disease, but drug interactions and metabolic effects require careful monitoring in

Mounjaro (tirzepatide) does not treat Cushing syndrome — it’s a GLP-1/GIP agonist for diabetes and weight loss, requiring separate management from

Mounjaro shows potential for lipedema through GLP-1 and GIP receptor action, but it’s not FDA-approved for this condition. Learn mechanisms, evidence, and

Mounjaro keto compatibility explained: tirzepatide works with low-carb diets but requires strategic carb cycling to prevent hypoglycemia and maintain

Mounjaro reduces obstructive sleep apnea severity by 50–60% through weight loss-driven airway remodeling—here’s how tirzepatide’s dual-agonist mechanism

Mounjaro reduces blood pressure by 4–6 mmHg systolic in clinical trials through weight loss and improved insulin sensitivity, not direct vascular action.

The first time most people have to give themselves a tirzepatide injection, there is usually a moment of hesitation. You stare at the pen…

Weight-related health conditions do not become less urgent after 65. In fact, obesity in older adults carries distinct risks that make effective treatment genuinely…

People with binge eating disorder navigating weight loss face a challenge that most standard approaches were not designed to address. The eating patterns that…